Add BrightSurf on Google Email

Science News Archive September 2004


Page 1 of 12

Elder abuse — A hidden tragedy

The Lancet article highlights the under-reported issue of elder abuse, affecting 2-10% of elderly people and increasing mortality risk by three times. A multidisciplinary approach involving family physicians, nursing, social workers, advocacy organisations, and law enforcement is crucial for accurate diagnosis and management.

SourceThe Lancet_DELETED·JournalThe Lancet·DateSep 30, 2004

Benchmark treatment for heart disorders safe for children of all ages

A new study published in the Journal of Cardiovascular Electrophysiology found radiofrequency ablation to be a safe and effective treatment for children with various forms of heart problems. The procedure showed high success rates, with over 98% of patients able to be cured, regardless of demographics or specific disorder location.

SourceBlackwell Publishing Ltd.·JournalJournal of Cardiovascular Electrophysiology·DateSep 30, 2004

E-learning attracts the 'usual suspects'

A Cardiff University study finds that e-learning attracts those who were already inclined to learn, with ICTs reinforcing existing patterns of education. Most adults use technology for informal purposes, such as hobbies and communication, rather than seeking formal learning.

Rare childhood genetic syndrome identified

Researchers have identified a rare genetic syndrome, Timothy syndrome, characterized by cardiac arrhythmias and atypical autism. The syndrome arises from a single gene mutation that impairs a fundamental calcium channel, leading to widespread cellular overloading. Calcium-channel blocking drugs may provide treatment for symptoms.

Phase II trials of second-generation antisense cancer drug planned following successful early study

The second-generation antisense cancer drug OGX-011 has shown promising results in a Phase I trial, inhibiting clusterin production in patients' cancers. The Phase II trials will investigate the effectiveness of OGX-011 combined with standard chemotherapy in patients with metastatic hormone refractory prostate, breast, and lung cancer.